#ACR24 research on #rheumatoidarthritis patients starting a 1st-line TNF therapy finds:
👉 Most who don’t respond to the treatment at 3 months still don’t respond by 12 months
👉 1 in 4 patients achieving low disease activity/remission at 3 months were no longer at 12 months
@abbvie
https://t.co/Iy7eSkAN7G
Do you have fatigue or pain from #lupus (SLE) even on your "good" days? New #ACR24 research showed that 24% of lupus patients experience moderate to severe symptoms even on their "good" days, which greatly impacts quality of life.
https://t.co/zrVVPgtx1l
For Shelley @shelley_fritz1, managing RA means becoming her own research expert. At #ACR24, she reveals how structured searches on PubMed helped her address GI symptoms and informed her treatment plan. Discover her empowering story here: https://t.co/n85FjbJgxh #GIHealth
Live from sunny D.C. and #ACR24! ☀️ This conference is more than just a meeting — it’s a celebration of hope, progress, and collaboration for those of us living with rheumatic diseases. Together, we���re shaping a brighter future. 🌟💊 #Rheumatology @venkyshilpa1
Are you satisfied with your rheumatoid arthritis control? 🤔 A new #ACR24 study reveals:
🩺 73% of 26,377 patients are satisfied, but 57.5% of those not 'very satisfied' want med changes.
🩺 Top concerns: fear new meds won’t work & thinking current meds are 'good enough.'
@venkyshilpa1@GHLF_Kelly
https://t.co/IWX2sCWm7L
Thank you to the @GHLForg for inviting us to the Clinical Trials Talks Podcast. We’re excited to collaborate & share @JuanaMataa & @estelamata's experiences as patient & caregiver. Our goal is to inspire & empower minority communities affected by autoimmune diseases like lupus.
🎉 100 essays! @ChronicEileen has reached an incredible milestone with https://t.co/auDGHOYF97, and we couldn’t be more grateful.
Eileen, your words have inspired countless patients and amplified the patient voice in ways that truly matter. Thank you for tackling the tough topics, sharing your heart, and being a powerful advocate. 💜
Read her latest: https://t.co/obsh6Y48ks
#RA #CreakyJoints #ACR24
#ACR24 Lupus Nephritis
• By Dr. Maria Dall'Era @UCSFRheum
Review of #LupusNephritis 🫘
▪️Rx TRIPLE therapy
▪️belimumab vs voclosporin
▪️low level proteinuria (even *UPCR <0.5*) can STILL be associated with disease activity (Class III/IV/V)
#Lupus#RheumTwitter#NephTwitter
🆕 The Great Debate at #ACR24: Is Mixed Connective Tissue Disease (MCTD) a distinct disease entity?
🗳️ Final Vote (n=430 votes)
• 51% = MCTD *is* a unique disease
• 49% = MCTD is not a unique disease
@DrLisaCS#MCTD#Rheumatology
How fast should #psoriaticarthritis treatments work? #ACR24 study shows patients who respond in 6 months have less pain, better quality of life, and improved results. @abbvie
https://t.co/sJQQAop39N.
A Mediterranean-style whole food plant-based diet shows promise for #gout and #cardiovascular health in new #ACR24 study:
✅ Lowers serum uric acid
✅ Reduces gout severity and pain
✅ Significant weight loss
✅ Improves LDL cholesterol
https://t.co/1hPXQBfZQZ
Findings on rheumatoid arthritis & common infections: ✅31% of monthly reports included infection, mostly upper respiratory
✅27% led to RA medication interruptions, higher with severe infections
✅Infections impacted fatigue & work productivity, with possible flare increase #ACR24
@venkyshilpa1@GHLF_Kelly@laurastradford@dave_curtis
https://t.co/kox2dfNYXN
#ACR24 study looked at giant cell arteritis (GCA) in Medicare fee-for-service and found that prevalence: ⬆️Rises with age (highest in 85+)
⬆️Is ~2x higher in females
⬆️Is highest in White persons
⬇️Is lowest in Asian persons
@abbVie@DrPeterMerkel
https://t.co/HKywDPQkPO
🦠 New at #ACR24! Data from rheumatoid arthritis patients & infection risks:
✅ No increased infection risk from biologics, JAK inhibitors, or low-dose steroids
✅ Higher infection rates from winter, rural areas, & past infections
✅ Comorbidities may play a bigger role than RA meds
@venkyshilpa1@GHLF_Kelly@laurastradford@dave_curtis
https://t.co/tbVEp6Nnvs